

REMARKS/ARGUMENTS

Reconsideration of this application is requested. Claims 23 and 29-33 remain active in the application subsequent to entry of this Amendment.

In order to advance examination of this application, claims 20-22 and 24-28 have been canceled thus leaving for consideration claims 23 and 29-33.

In the Official Action three separate prior art-based rejections are raised the examiner relying on three separate pieces of prior art but not specifying which portion or portions of the document are specifically relied upon but merely commenting "see the entire document". Because of this lack of specificity it has been difficult for applicants to determine exactly which portions of these documents are thought to be pertinent to the claims in this application. It is acknowledged that one or more of them are pertinent to claim 20 and thus claim 20, and claims dependent from it, have been withdrawn. This then leaves claim 23 as the main independent claim now under review.

Among the amine compounds recited in claim 23, Sakai et al (US 6,410,608) discloses 6-dimethylamino-1-hexanol, and Bogdan et al (US 6,086,788) and Lund et al (US 5,866,029) disclose N,N-dimethylethanolamine.

Claim 23 has been amended to exclude the above-mentioned compounds for reasons that will be apparent. Accordingly, all three prior art-based rejections are no longer pertinent as none of the cited documents anticipates claim 23.

With respect to the provisional obviousness-type double patenting rejection, the issue fee on parent application Serial No. 10/187,417 was paid on May 3, 2004 and thus it is expected to issue as a patent shortly. Accordingly, please see the attached Terminal Disclaimer which will resolve the examiner's double patenting-based concerns.

Reconsideration and favorable action are requested.